Women and Middle-Class Patients Lead UK Private Weight Loss Jab Prescriptions
Nearly 80% of private weight-loss drug prescriptions in the UK are for women, with middle-class patients in less deprived areas more likely to access treatment early, research shows.
- The Health Foundation's analysis found almost 80% of private prescriptions for GLP‑1 drugs go to women, based on 113,630 patients between November 2024 and October 2025 with Voy.
- NHS England has put in place a phased rollout of Mounjaro over 12 years, prioritising 220,000 patients in the first three years, so most users currently pay privately.
- The analysis found people in the most deprived areas are around a third less likely to get jabs, with 45% of 30 to 49-year-olds there starting treatment at BMI of 35 or above compared to 30% in the least deprived areas.
- The Health Foundation cautioned that patients who start treatment later tend to be heavier, risking health, while NHS England warned this demand could occupy 18% of GP appointments.
- Semaglutide is available on the NHS, 2.4 million people use weight‑loss medications, and last month’s ban on junk‑food adverts renewed calls for prevention.
9 Articles
9 Articles
Women and the middle classes dominate take-up of weight loss jabs
Analysis of private prescriptions for drugs like Mounjaro show that almost 80% are for women
Women and the middle classes dominate take up of weight loss jabs
Women and the middle classes are dominating take up of weight loss injections, research suggests. Analysis of private prescriptions for drugs like Mounjaro show that almost 80% are for women, while the highest uptake is among men and women aged 30 to 49, falling sharply after the age of 60. The Health Foundation, working with online weight management provider Voy, analysed 113,630 patients who received a private prescription between November 202…
Coverage Details
Bias Distribution
- 57% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium







